Buchumschlag

The Open Hand Initiative: Facilitating the Use of Real‐World Evidence in Regulatory Submissions Through Collaboration and Transparency

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Elodie Baumfeld Andre, Matthew Gee, Carsten Magnus, Stephanie Greeman, Pipper White, Maryellen de Mars, Brad Spring
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Clinical Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

The Use of Real‐World Evidence for Regulatory Decisions in China
von: Jiayue Xu, et al.
Veröffentlicht: (2024)

Real‐World Evidence in Regulatory Decision Making: Time for Evidence Integration
von: Rebecca A. Miksad
Veröffentlicht: (2024)

Off‐Label Use of Mycophenolate: Can Real‐World Evidence Fetch Regulatory Approval for Lupus Nephritis and Other Indications?
von: Nisha Sharma, et al.
Veröffentlicht: (2024)

Return to SENDer: The Submitted Electronic Data for Nonclinical Cardiovascular Studies is Not Facilitating Transparency, Translation or Innovation
von: Matthew M. Abernathy, et al.
Veröffentlicht: (2024)

Real‐World Evidence to Inform Regulatory Decision Making: A Scoping Review
von: Marieke S. Jansen, et al.
Veröffentlicht: (2024)

Advancing Principled Pharmacoepidemiologic Research to Support Regulatory and Healthcare Decision Making: The Era of Real‐World Evidence
von: Rohini K. Hernandez, et al.
Veröffentlicht: (2025)

FRAME: Framework for Real‐World Evidence Assessment to Mitigate Evidence Uncertainties for Efficacy/Effectiveness – An Evaluation of Regulatory and Health Technology Assessment Decision Making
von: Gianmario Candore, et al.
Veröffentlicht: (2025)

Pharmacogenomic Prescribing Guidelines: Are They Always Useful?
von: Magnus Ingelman‐Sundberg
Veröffentlicht: (2024)

Dietary‐Driven Gene Expansion
von: Magnus Ingelman‐Sundberg
Veröffentlicht: (2025)

Letter: Reconsidering Tenofovir Disoproxil Fumarate Use in Light of Emerging Safety Evidence
von: Priyadarshini Zula, et al.
Veröffentlicht: (2026)

Regulatory Issues of Platform Trials: Learnings from EU‐PEARL
von: Quynh Lan Nguyen, et al.
Veröffentlicht: (2024)

Dosage Optimization: A Regulatory Perspective for Developing Oncology Drugs
von: Atiqur Rahman, et al.
Veröffentlicht: (2024)

Progress in Pharmacometrics Implementation and Regulatory Integration in Africa: A Systematic Review
von: Bonginkosi S'fiso Ndzamba, et al.
Veröffentlicht: (2024)

Advancing Pharmacoequity Globally: Reflections from the ASCPT Development, Regulatory, and Outcomes Network
von: Priya Jayachandran, et al.
Veröffentlicht: (2026)

Regulatory Interactions and Learnings— RADIAL the Trials@Home Proof‐of‐Concept Trial on Decentralization
von: Helga Gardarsdottir, et al.
Veröffentlicht: (2025)

Extended Model‐Informed Drug Development: Beyond Clinical Trials and Regulatory Approval
von: Mohamed A. Kamal, et al.
Veröffentlicht: (2024)

The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report
von: Anna M. G. Pasmooij, et al.
Veröffentlicht: (2024)

Use of Real‐World Data and Real‐World Evidence in Rare Disease Drug Development: A Statistical Perspective
von: Jie Chen, et al.
Veröffentlicht: (2025)

Reply to “On Selection and Analytical Transparency in the FRAME Framework for RWE Evaluation”
von: Gianmario Candore, et al.
Veröffentlicht: (2026)

Building a Robust Investigator‐Initiated Platform: The I‐ CARE Experience
von: Julien Kirchgesner, et al.
Veröffentlicht: (2026)

French‐Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten
von: Louis Lebreton, et al.
Veröffentlicht: (2024)

Impact of Regulatory Post‐Market Safety Advisories on Prescribing Practices: An Interrupted Time Series Analysis
von: Seonji Kim, et al.
Veröffentlicht: (2025)

Regulatory Perspective Based on Survey of Relationship Between Biopharmaceutical Characteristics and Food Effects on Systemic Pharmacokinetics
von: Naoko Honma, et al.
Veröffentlicht: (2025)

Characteristics of Drugs from Non‐Global Companies for Hematologic Malignancies and Impact on Global Regulatory Approval
von: Kensuke Matsuda, et al.
Veröffentlicht: (2024)

Regulatory Approval of CAR‐T Cell and BsAb Products for Lymphoid Neoplasms in the US, EU, and Japan
von: Kensuke Matsuda, et al.
Veröffentlicht: (2025)

The Rare Disease Moonshot: Paradigms Shift, Translational Medicine, and Regulatory Science for the World's Rarest Conditions
von: Cécile Ollivier, et al.
Veröffentlicht: (2024)

Corrections to “Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions”
Veröffentlicht: (2024)

Correction to Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions
Veröffentlicht: (2024)

Capability Development in the European Medicines Regulatory Network—A European Learning Needs Analysis and Survey Study
von: Naomi Beard, et al.
Veröffentlicht: (2025)

Regulatory Pathways for Qualification and Acceptance of Digital Health Technology‐Derived Clinical Trial Endpoints: Considerations for Sponsors
von: Jessie P. Bakker, et al.
Veröffentlicht: (2024)

Biomarker Utilization for Regulatory Decision Making: A Landscape Analysis of Neurological Drug Products Approved by FDA (2008–2024)
von: Dahee Jung, et al.
Veröffentlicht: (2025)

Clinical Benefit, Trials, and Regulatory Approval of Oncology Indications Under Multiple Expedited Programs for Drug Marketing in China, 2018–2024
von: Jie Zhang, et al.
Veröffentlicht: (2025)

Identification of a Safe and Tolerable Carbamazepine Dosing Paradigm that Facilitates Effective Evaluation of CYP3A4 Induction
von: Amita Datta‐Mannan, et al.
Veröffentlicht: (2024)

Clinical Evidence 2030
von: Peter Arlett, et al.
Veröffentlicht: (2025)

Integrated Evidence Planning for Enhancing Patient Care: Harnessing the Power of Real‐World Evidence
von: Gorana Capkun, et al.
Veröffentlicht: (2025)

Editorial: Three‐Dimensional (3D) Geometric Modelling in TIPS Implantation—A Further Step Toward Personalised Portal Pressure Reduction and Pre‐Procedural Planning. Authors' Reply
von: Markus Kimmann, et al.
Veröffentlicht: (2025)

Letter: Social work and clinical synergy—Optimizing health interventions for elderly DGBI populations: Authors' reply
von: Ami D. Sperber, et al.
Veröffentlicht: (2024)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis
von: Stephanie Tsai, et al.
Veröffentlicht: (2025)

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative
von: Joel L. Weissfeld, et al.
Veröffentlicht: (2026)

Harmonizing HTA Evidence Needs and Expectations: Challenges and Opportunities to Improve Evidence Generation, Ensure Access and Affordability
von: Sarah K. Emond, et al.
Veröffentlicht: (2025)